KIR2DS2 and KIR2DS4 promoter hypomethylation patterns in patients undergoing hematopoietic cell transplantation (HCT)

Ghislaine Gallez‐Hawkins(City Of Hope National Medical Center), John A. Zaia(City Of Hope National Medical Center), David Senitzer(City of Hope), Ryotaro Nakamura(City Of Hope National Medical Center), Ketevan Gendzekhadze(City Of Hope National Medical Center), Xiuli Li(Agricultural Genomics Institute at Shenzhen), Anne Franck(City of Hope), Stephen J. Forman(City Of Hope National Medical Center)
Human Immunology
August 29, 2012
10.1016/j.humimm.2012.08.013
Cited by 1

Related Papers

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
|Blood|2000|1.6k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754